प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
Dogwood Therapeutics: Halneuron के फेज 2b CINP अध्ययन का टॉपलाइन डेटा 2026 के पतझड़ में आएगा
The 8-K confirms the Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain remains on track with 164 patients enrolled and top-line results guided for fall 2026. Separately, the FDA accepted the SP16 IND for a Phase 1b CIPPN study that will begin enrolling mid-2026.
मुख्य तथ्य
स्रोत का अंश
EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders - ALPHARETTA, Ga., May 14, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the
इस संपत्ति पर और
उल्लेखनीय
20 जुल॰ 2026
12:30 pm
DWTXDogwood Therapeuticsडॉगवुड: हेलन्यूरॉन चरण 2बी सीआईएनपी परीक्षण में 200 रोगी नामांकित
उल्लेखनीय
26 मार्च 2026
01:00 pm
DWTXDogwood Therapeuticsडॉगवुड थेरेप्यूटिक्स: Halneuron के फेज़ 2b HALT-CINP ट्रायल में 145 मरीज़ों की भर्ती
उल्लेखनीय
20 जन॰ 2026
01:30 pm
DWTXDogwood Therapeuticsडॉगवुड थेरेप्यूटिक्स: Halneuron के फेज़ 2b का अंतिम डेटा Q3 2026 में अपेक्षित